Wells Fargo & Company Forecasts Strong Price Appreciation for Immunovant (NASDAQ:IMVT) Stock

Key Points

• Wells Fargo raised its Immunovant price target to $47 from $45 and reiterated an “overweight” rating, implying about 32% upside from the cited share price of $35.62. Analysts’ average target was $44.30, with a “Moderate Buy” consensus.
• IMVT-1402 met the primary endpoint in a rheumatoid arthritis trial: 92.5% of patients on the 600 mg dose achieved an ACR20 response at Week 28, versus 75.6% on placebo. Immunovant plans to discuss next regulatory steps with the FDA.
• Immunovant reported a quarterly loss of $0.47 per share, narrower than the estimated $0.74 loss, but said it is unlikely to develop IMVT-1402 for Sjögren’s disease beyond its ongoing Phase 2 trial.

Immunovant (NASDAQ:IMVT - Get Free Report) had its target price hoisted by stock analysts at Wells Fargo & Company from $45.00 to $47.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Wells Fargo & Company's price objective would suggest a potential upside of 31.96% from the stock's current price.

Several other equities analysts have also issued reports on the stock. HC Wainwright reissued a "buy" rating on shares of Immunovant in a report on Thursday, September 24th. UBS Group reaffirmed a "buy" rating on shares of Immunovant in a research report on Wednesday, September 23rd. Sanford C. Bernstein upgraded Immunovant to a "hold" rating in a report on Wednesday, July 29th. Cantor Fitzgerald reissued an "overweight" rating on shares of Immunovant in a research report on Tuesday, August 25th. Finally, JPMorgan Chase & Co. upped their price objective on Immunovant from $47.00 to $50.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Immunovant currently has an average rating of "Moderate Buy" and an average target price of $44.30.

Immunovant Stock Up 1.3%

IMVT traded up $0.47 during trading hours on Tuesday, reaching $35.62. 100,063 shares of the company's stock traded hands, compared to its average volume of 1,508,490. The firm has a 50-day moving average price of $32.98 and a 200 day moving average price of $32.15. The firm has a market capitalization of $7.36 billion, a PE ratio of -12.70 and a beta of 0.95. Immunovant has a 52-week low of $21.86 and a 52-week high of $45.42.

Immunovant (NASDAQ:IMVT - Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.27. During the same quarter in the prior year, the business posted ($0.73) EPS. Equities analysts predict that Immunovant will post -2.96 EPS for the current fiscal year.

Insiders Place Their Bets

In other Immunovant news, COO Melanie Gloria sold 2,241 shares of the company's stock in a transaction on Wednesday, October 7th. The shares were sold at an average price of $32.06, for a total value of $71,846.46. Following the sale, the chief operating officer directly owned 217,060 shares of the company's stock, valued at approximately $6,958,943.60. This represents a 1.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Christopher Van Tuyl sold 2,846 shares of the stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $36.36, for a total value of $103,480.56. Following the sale, the insider directly owned 176,545 shares in the company, valued at $6,419,176.20. This represents a 1.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 24,430 shares of company stock valued at $787,852. Insiders own 1.90% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMVT. HighTower Advisors LLC increased its stake in shares of Immunovant by 0.8% during the third quarter. HighTower Advisors LLC now owns 56,541 shares of the company's stock worth $1,910,000 after purchasing an additional 437 shares in the last quarter. Ground Swell Capital LLC acquired a new position in shares of Immunovant during the 3rd quarter worth about $323,000. Aberdeen Group plc lifted its stake in Immunovant by 2.6% in the 3rd quarter. Aberdeen Group plc now owns 879,334 shares of the company's stock valued at $29,704,000 after buying an additional 22,304 shares in the last quarter. Fisher Asset Management LLC purchased a new position in Immunovant in the 3rd quarter valued at about $18,435,000. Finally, AlphaCentric Advisors LLC acquired a new stake in Immunovant in the 3rd quarter worth about $415,000. Hedge funds and other institutional investors own 47.08% of the company's stock.

Key Headlines Impacting Immunovant

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: IMVT-1402 met the primary endpoint in a potentially registrational trial for difficult-to-treat rheumatoid arthritis: 92.5% of patients receiving the 600 mg dose achieved an ACR20 response at Week 28, versus 75.6% on placebo (p=0.0139). Exploratory ACR50 and ACR70 responses also reached 80.0% and 52.5%, respectively. Immunovant plans to discuss the next regulatory steps with the FDA later this year, making those discussions an important upcoming catalyst. Immunovant corporate updates and financial results
• Positive Sentiment: Immunovant reported a loss of $0.47 per share, narrower than analysts’ estimate of a $0.74 loss and the $0.73 loss a year earlier. The earnings beat may provide a modest positive alongside the clinical update. Second-quarter earnings results
• Negative Sentiment: The company said it is unlikely to advance IMVT-1402 in Sjögren’s disease beyond its ongoing, fully enrolled Phase 2 trial, citing the evolving landscape and recent data in the field. This narrows the drug’s potential development opportunities, though other clinical timelines remain on track. Immunovant corporate updates and financial results

Immunovant Company Profile

Immunovant, Inc is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies.

The company's investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves' disease and other autoimmune disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.